CELGENE CORP (NASDAQ: CELG)





$55.50 0.73 (1.33%)
Real-time 12:00:00 AM ET
Turn On
KEY STATS
52-Week High Price
59.67
52-Week Low Price
36.90
Avg Volume (3 Mo.)
3.00 M
Market Cap
25.17 B
P/E Ratio (TTM)
33.0
Diluted EPS (TTM)
2.34
Shares
459.60 M
Dividend Rate ($) / (%)
0.00/0.00
92%
8%
You need to upgrade your Flash Player to view the graph.
View by Date Range:
12 Mo. Price Change : 1% - CELG has underperformed the S&P 500 by 25%
SIMILAR COMPANIES
NameCurrent Price - Today's ChangeMarket Cap
TEVA PHARMACEUTICAL LTD (TEVA) $57.10 -  $0.18(0.32%)51.77 B
BRISTOL-MYERS SQUIBB CO (BMY) $24.25 -  $0.29(1.21%)47.48 B
GILEAD SCIENCES INC (GILD) $46.30 -  $0.21(0.46%)41.74 B
ELI LILLY & CO (LLY) $35.20 -  $0.42(1.21%)39.66 B
NOVO NORDISK A/S (NVO) $69.52 -  $0.38(0.55%)36.54 B
ALLERGAN INC (AGN) $58.75 -  $0.58(1.00%)17.85 B
BIOGEN IDEC INC (BIIB) $54.09 -  $1.25(2.37%)15.48 B
GENZYME CORP (GENZ) $54.87 -  $0.38(0.70%)14.64 B
SHIRE PLC ADS (SHPGY) $58.49 -  $0.80(1.39%)10.77 B
FOREST LABORATORIES INC (FRX) $28.98 -  $0.20(0.69%)8.69 B
STOCK ANALYSIS
Stock Analysis
The Best Performing Stocks Of The Decade (SWN, XTO, GILD, SRCL, CELG)
Investors who were able to see past the losses and volatility that some of these companies had in the beginning wer...
Stock Analysis
Biotech Poised to Disappoint (MRK, GILD, CELG)
The recent wave of big pharma acquisitions does not live up to hype.
Stock Analysis
Sequenom Stock Testing Signs Of Life (SQNM)
Sequenom stock has climbed on the success of a new diagnostic product. Is there any place to go but "down"?
Stock Analysis
5 Biotech Stocks To Watch In '09 (DNA, AMGN, GILD, CELG, GENZ)
When the market starts to look sickly, can you turn to Biotechs to inject health into your portfolio? Here are five...
Stock Analysis
Stem Cell Regeneration For Wounded Bulls (AMGN, CELG, KOOL, STEM)
In the present volatile market, risk-averse investors may want to consider stem cell stocks.
CELG RELATED HEADLINES
arrow
Celgene (CELG) Fourth Quarter Earnings Preview
Celgene (NASDAQ: CELG) opened at $57.61. So far today, the stock has hit a low of $57.35 and a high of $58.18. CELG is now trading at $57.69, down $0.17 (-0.29%). The stock hit its 52-Week high of $59.67 earlier this month and set its 52-Week low of $36.90 in April. CELG is going to reporting its fourth quarter numbers tomorrow. Analysts are expecting to see the company post earni...

At Market Intelligence Center 1/27/2010
arrow
Option Skews - Relatively Heavy Call Activity on Celgene Corp, Advanced Micro Devices Inc, Rambus Inc, First Solar Inc
Here are the stocks that saw a bias toward call activity in the previous session.This filtered scan is based on the International Securities Exchange (ISE) buy-to-open data...(Read More)

By SchaeffersResearch 1/20/2010
arrow
Flying With Airlines, Apple And Google
Airlines are the antithesis of great growth stocks, but why fight the market when it rewards speculation?

Forbes.com 1/14/2010
arrow
Celgene (CELG) Trading High Following Broker Upgrade
Celgene (CELG) was upgraded today by analysts at EVA Dimensions, LLC and the stock is now at $57.19, up $0.20 (0.35%) on volume of 1,421,762 shares traded. EVA Dimensions, LLC upgraded the stock today to Buy from Overweight. Over the last 52 weeks the stock has ranged from a low of $36.90 in April to a high of $58.66 earlier this month. Celgene stock has been showing support around...

At Market Intelligence Center 1/13/2010
arrow
Celgene (NASDAQ: CELG) NewsBite
Celgene (NASDAQ: CELG) opened at $54.32. So far today, the stock has hit a low of $54.02 and a high of $56.16. CELG is now trading at $55.85, up $5.23 (10.33%). Over the last 52 weeks the stock has ranged from a low of $36.90 to a high of $58.31. CELG shares are on the move this morning after a late-stage study of its blood cancer drug Revlimid was stopped early because of its effectiveness. On the...

At Market Intelligence Center 12/18/2009
arrow
Celgene's Boon; Genzyme Takes Flack; A Genomic Vision
Celgene shares are up more than 10% on news that a study sponsored by the National Institutes of Health showed that patients with multiple myeloma who got he biotech company's blood cancer drug, Revlimid, following a stem cell transplant did better than those who didn't. The study is a boost for the idea of giving ...

Forbes.com 12/18/2009
Stock Simulator- Free Account
Chart Advisor- Free Report
Sponsored Links
COLOSIM1